Amgen's Q2 Beat and Raised Guidance Bolster Long-Term Growth Narrative

Amgen Inc.'s recent second-quarter results and updated full-year guidance have provided new support for its long-term growth narrative.

The biotech company's revenue of US$10,054 million and net income of US$2,375 million in the quarter outpaced expectations. Additionally, Amgen issued revised full-year 2026 targets, with a projected range of total revenue between US$38.20 billion and US$39.40 billion, and GAAP earnings per share (EPS) of US$15.80 to US$17.08.

The updated guidance reinforces the current earning base supporting Amgen's pipeline-driven growth story. However, despite this improved outlook, investors should remain aware of ongoing risks related to biosimilar competition and potential price cuts.